{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"44.2","upperLimit":"77.6","value":"62.9"},{"groupId":"OG001","lowerLimit":"28.5","upperLimit":"54.5","value":"40.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"189"},{"groupId":"OG001","value":"187"}],"units":"Participants"}],"description":"OS defined as time from date of randomization to date of death due to any cause.\n\nIf the patient was alive at the date of the analysis cut-off or lost to follow-up, then OS was censored at the last contact date prior to data cut-off date. The distribution of OS was estimated using the KM method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ceritinib administered continuously through oral dosing at a dosage of 750 mg once daily in fasted state","id":"OG000","title":"Ceritinib"},{"description":"Pemetrexed plus cisplatin or carboplatin (based on Investigator's choice) for 4 cycles (Induction) followed by pemetrexed as single agent (Maintenance)","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"The Full Analysis Set (FAS) consisted of all patients to whom study treatment had been assigned by randomization","reportingStatus":"POSTED","timeFrame":"From date of randomization to date of death due to any cause, up to approximately 120 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}